Cocrystal Pharma, Inc. (COCP)
| Market Cap | 22.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -38.02M |
| Shares Out | 8.14M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Oct 11, 2022 |
| Volume | 29,186 |
| Open | 2.58 |
| Previous Close | 2.74 |
| Day's Range | 2.58 - 2.84 |
| 52-Week Range | 2.05 - 9.72 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 20.79 (+665.7%) |
| Earnings Date | Nov 21, 2022 |
About COCP
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials f... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for COCP stock is "Buy." The 12-month stock price forecast is 20.79, which is an increase of 665.75% from the latest price.
News
Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza ...
Affirms plans to report topline P hase 1 results in 2022 and to initiate P hase 2a influenza human challenge trial in 2023
Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatmen...
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable safety profile in both the single-ascending dose and the mu...
Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiv...
BOTHELL, Wash., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces it has been granted European patent EP3866778 titled "Combinations Of Inhibitors of Influenza Virus Repl...
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344
BOTHELL, Wash., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability and...
Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference
BOTHELL, Wash., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and interim co-CEO, will present a company overview at the Dawson James Securitie...
Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split
BOTHELL, Wash., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that its Board of Directors has approved a 1-for-12 reverse stock split of th...
Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectru...
BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ...
Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - August 3, 2022) - The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (NASDAQ: COCP) ("the Company"), a clinical-stage biotechnology company discovering and develop...
Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference
BOTHELL, Wash., May 18, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a Company...
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Progr...
BOTHELL, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the three months ended March 31, 2022, and provides updates on its antiviral pipeline...
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at...
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial
Cocrystal Pharma Inc (NASDAQ: COCP) reported preliminary results of a Phase 1 study with CC-42344, a broad-spectrum oral antiviral to treat pandemic and seasonal influenza A. The ongoing Phase 1 trial, ...
Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectr...
CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
BOTHELL, Wash., March 23, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial results for the 12 months ended December 31, 2021, and provides updates on its antiviral pipeli...
Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference
BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group and ho...
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated A...
BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy adul...
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19
CDI-988 and CDI-873 target a highly conserved region in the active site of SARS-CoV-2 main (3CL) protease required for viral RNA replication.
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Novel broad-spectrum oral lead candidates CDI-988 and CDI- 873 , discovered using Cocrystal's antiviral drug discovery platform , demonstrate superior in vitro potency against SARS-CoV-2 and activity ag...
Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205
Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022
Cocrystal's COVID-19 Antiviral Candidate Shows Potency Against Omicron Variant
Cocrystal Pharma Inc's (NASDAQ: COCP) COVID-19 antiviral candidate has shown antiviral potency against the omicron variant in vitro studies. The Company earlier confirmed that its protease inhibitors d...
Cocrystal Pharma's COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Again...
Antiviral activity now confirmed against SARS-CoV-2 and all variants of concern including Omicron, Delta, Alpha, Beta and Gamma
Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Mark...
BOTHELL, Wash., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that President and interim CEO Sam Lee, Ph.D. and CFO and interim CEO Jam...
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at ...
Unveils designs for Phase 1 and 2 stud ies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors ; trial initiations expected in 2022
Cocrystal Pharma, Inc. (COCP) Reports Q3 Loss, Lags Revenue Estimates
Cocrystal Pharma, Inc. (COCP) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Cocrystal Pharma, Inc. (COCP) Report Negative Q3 Earnings? What You Should Know
Cocrystal Pharma, Inc. (COCP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.